Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer.

[1]  N. Mulder,et al.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Sznol,et al.  Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. , 1992, Cancer research.

[3]  J. Sosman,et al.  Activation of Human T Cells Obtained Pre‐ and Post‐Interleukin‐2 (IL‐2) Therapy by Anti‐CD3 Monoclonal Antibody plus IL‐2: Implications for Combined In Vivo Treatment , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[4]  R. Stein,et al.  The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected] , 1991, British Journal of Cancer.

[5]  G. Hemstreet,et al.  Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. , 1990, Cancer research.

[6]  J. Bluestone,et al.  Activation of human T cells in vivo following treatment of transplant recipients with OKT3. , 1990, Transplantation.

[7]  J. Bluestone,et al.  Neurotoxicity after treatment with muromonab-CD3. , 1990, The New England journal of medicine.

[8]  H. Kirchner,et al.  Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies , 1990, The Lancet.

[9]  C. Ferran,et al.  Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. , 1989, The New England journal of medicine.

[10]  P. Vereerstraeten,et al.  RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.

[11]  P. Anderson,et al.  Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. , 1989, Cancer research.

[12]  J. Bluestone,et al.  Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. , 1989, Journal of immunology.

[13]  J. Bluestone,et al.  In vivo administration of anti-CD3 prevents malignant progressor tumor growth. , 1988, Science.

[14]  J. Bluestone,et al.  Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. , 1988, Journal of immunology.

[15]  H. Muss.  Interferon therapy for renal cell carcinoma. , 1987, Seminars in oncology.

[16]  F. Bach,et al.  Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. , 1987, Journal of immunology.

[17]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[18]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[19]  D. Carson,et al.  Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. , 1985, Journal of immunology.

[20]  M. Crow,et al.  Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1. , 1985, Journal of immunology.

[21]  G. Currie.  Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. , 1972, British Journal of Cancer.